Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Osimertinib for maintenance treatment of locally advanced, unresectable EGFR mutation-positive non-small-cell lung cancer during or following chemoradiation therapy

5 October 2026

Condition

Cancer

-

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended osimertinib for inclusion on the MOH List of Subsidised Drugs for maintenance treatment of locally advanced, unresectable epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer during or following chemoradiation therapy. The decision was based on the uncertain extent of clinical effectiveness, unfavourable cost effectiveness compared with active surveillance, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claims eligibility for osimertinib are provided in the Annex.

Osimertinib for maintenance treatment of locally advanced, unresectable EGFR mutation-positive non-small-cell lung cancer during or following chemoradiation therapy (Published 05 Oct 2026) [PDF, 291.92 KB] (opens in new tab)